Screener
Veracyte VCYT Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Income tax provision | 1,267 | 381 |
| Net income | $28,707 | $7,047 |
| Earnings per share: | ||
| Basic | $0.36 | $0.09 |
| Diluted | $0.35 | $0.09 |
| Shares used to compute earnings per common share: | ||
| Basic | 79,536,601 | 78,028,254 |
| Diluted | 81,313,588 | 80,056,024 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's shares (diluted)?
- Veracyte (VCYT) reported shares (diluted) of 81.3M in Q1 2026.
- How has Veracyte's shares (diluted) changed year-over-year?
- Veracyte's shares (diluted) increased by 1.6% year-over-year, from 80.1M to 81.3M.
- What is the long-term trend for Veracyte's shares (diluted)?
- Over 4 years (2021 to 2025), Veracyte's shares (diluted) has grown at a 4.4% compound annual growth rate (CAGR), from 268.3M to 318.7M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Veracyte's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude